A day before would-be buyer Valeant Pharmaceuticals is set to unveil a second, unsolicited takeover bid, its acquisition target,
It offered to pay $46 billion in cash and stock last month for Allergan, but the Botox maker rejected the offer earlier this month, criticizing it for being too low. In rejecting the offer, Allergan also defended itself against suggestions by Valeant and Ackman that it spent too much on research and development and that the company could be more profitable if it cut expenses.
Allergan's presentation, filed Tuesday with the
In its presentation, Allergan said Valeant's sales growth has been primarily driven by "unsustainable" price increases and that the company lacked the experience in "managing complex global businesses."
Allergan said the slide show presentation was compiled by outside financial consultants and forensic accountants using publicly available data.